

Emilie HÉNIN, Martin BERGSTRAND, Mats O. KARLSSON

Department of Pharmaceutical Biosciences, Uppsala University, Sweden

Objectives

To investigate the possibility of using prior information on tablet movement through Gastro-Intestinal (GI) tract for a semi-mechanistic modeling of absorption processes.

Methods

Magnetic Marker Monitoring (MMM) technique:

- Visualize the transit of labeled tablet through GI tract
- Monitor tablet disintegration and drug release

Felodipine data: 6 healthy volunteers in MMM study [1]

 administered magnetically labeled extended release tablets containing felodipine

Antrum


under fed and fasting conditions


3 types of observations:

- Plasma concentrations of felodipine
- Tablet GI position
- In vivo drug release

Previously proposed Models ^[2]: GI tablet transit model


Markov chain model for tablet position, where the probability of observing tablet in different GI position is dependent on the last observed position and time since last observation.





Mean Residence Time Approach Coll


- Both models were coupled and estimated simultaneously
- Using prior population estimates for tablet GI transit
- Without using tablet position as Antrum covariate
- Mixture modeling for patients ^{Fundus} with 0, 1 or 2 return from antrum to fundus




Results and Discussion

Empirical Bayes Estimates for each parameter obtained using NONMEM VI

Comparision of tablet movement profiles



Comparison of Felodipine plasma concentration profiles



MRT approach can predict correctly in several individuals GI tablet position and concentration profiles.

Similar results were obtained when only plasma concentration data were used.


Conclusions and Perspectives

This work represents a first step in the use of prior information on GI tablet movement in absorption modeling.

This approach will be applied to other substances and formulations in order to investigate the possibility of better characterising erratic concentration profiles.

References

- 1. Weitschies W et al, J Control Release, 2005
- 2. Bergstrand M et al, Clin Pharmacol Ther, 2009



Fundus